Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor β1, and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia

Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor β1, and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia

Shosaku Nomura, Tomoki Ito, Atsushi Satake, Kazuyoshi Ishii First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan Background: The outcome for chronic myelogenous leukemia (CML) patients presented in the chronic phase has changed dramatically since the introduction...

Full description

Bibliographic Details
Main Authors: Nomura S, Ito T, Satake A, Ishii K
Format: Article
Language:English
Published: Dove Medical Press 2018-12-01
Series:Journal of Blood Medicine
Subjects:
CML
dasatinib
LGL
PDMP
TGFβ1
sCTLA-4
Online Access:https://www.dovepress.com/assessment-of-soluble-cytotoxic-t-lymphocyte-associated-antigen-4-tran-peer-reviewed-article-JBM

Internet

https://www.dovepress.com/assessment-of-soluble-cytotoxic-t-lymphocyte-associated-antigen-4-tran-peer-reviewed-article-JBM

Similar Items